Fig. 1 · Structure

Documents & Downloads

AZD-3965

Cat. No. A14186 CAS 1448671-31-5

MCT1 inhibitor

AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.

In Stock

Publications for AZD-3965

1 publication citing this product

  1. Lu Gao, .et al. , Int J Biol Sci, 2022, Jan 1;18(2):599-616 PMID: 35002512

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AZD3965 binds MCT1 with nanomolar affinity. Competitive binding gave a Ki of 1.6 nM in Jurkat membranes; matched recombinant-membrane assays gave Ki values of 3.2 nM for MCT1 and 20.0 nM for MCT2. These are binding endpoints, not treatment doses. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MCT1

AZD-3965 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of AZD-3965 from 4 published references.

AZD-3965 In Vitro Studies

AZD3965 responses varied among SCLC models and with oxygen availability. At 8 nM for 72 hours, intracellular lactate increased 3.7-fold in hypoxic COR-L103 cells and 3.7- and 3.9-fold in normoxic and hypoxic NCI-H1048 cells, respectively. DMS79 was comparatively unresponsive; metabolic viability signals were checked against direct cell counts. [2]

Competitive binding to MCT1 and MCT2

Biochemical assay · Jurkat cell membranes; yeast membranes expressing recombinant human MCT1 or MCT2 [1]

AZD3965 displaced MCT ligands, with higher affinity for MCT1 than MCT2 in the matched recombinant-membrane assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to MCT1 in Jurkat membranesKi; pKi ± s.e. Ki 1.6 nM; pKi 8.80 (0.13); n = 6[1]
Binding to recombinant human MCT1 and MCT2Ki MCT1: 3.2 nM; MCT2: 20.0 nM; n = 2[1]

Literature-Reported Treatment Conditions

Method
Competitive radioligand binding
Reported limits
Treatment dose/time and vehicle are not specified in the selected binding methods; Ki is an assay result, not a treatment concentration.
Methods and source locations

Compound reported in the paper: AZD3965

Results apply to the paper-reported material and model; no analytical equivalence or current Adooq lot validation is established.

Table 1A-B; Results: AZD3965 demonstrates high affinity and selectivity to MCT1; binding/selectivity methods; Figure 1

Binding to MCT1 in Jurkat membranes: Competition against [125I]-MCT1 ligand using wheatgerm-agglutinin scintillation proximity beads. — Table 1A; MCT1 binding affinity methods

Binding to recombinant human MCT1 and MCT2: Filter binding by displacement of [3H]-MCT1 or MCT2 ligand. — Table 1B; MCT2 selectivity assays

Oxygen-dependent SCLC response and intracellular lactate

Cell-based study · SCLC panel; detailed COR-L103, NCI-H1048, DMS79 and DMS114 comparisons under normoxia or 1% O2 [2]

At 8 nM for 72 hours, AZD3965 reduced cell number in selected SCLC models and increased intracellular lactate in responsive conditions; responses were heterogeneous.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intracellular lactate relative to untreated cells under the same oxygen conditionFold change COR-L103 hypoxia: 3.7-fold; NCI-H1048 normoxia: 3.7-fold; NCI-H1048 hypoxia: 3.9-fold; other tested conditions: <1.9-fold[2]
Cell number relative to untreated cells under the same conditionReported significance of reduction Hypoxic COR-L103 p=0.002; normoxic NCI-H1048 p=0.011; hypoxic NCI-H1048 p=0.0023; hypoxic DMS114 p=0.038[2]

Literature-Reported Treatment Conditions

Treatment concentration
8 nM
Exposure duration
72 h
Method
Cell treatment; hypoxic cultures preconditioned at 1% O2 for 8 h
Vehicle
DMSO stock; final DMSO concentration not reported in selected methods
Reported limits
No exact cell-number effect sizes inferred from bars.
Methods and source locations

Compound reported in the paper: AZD3965

Results apply to the paper-reported material and model; no analytical equivalence or current Adooq lot validation is established.

Figure 1A-D and caption; Results: Sensitivity of SCLC cell lines to AZD3965; Cell Culture and Drugs, Concentration Response Assays, Measurements of Lactate

Intracellular lactate relative to untreated cells under the same oxygen condition: L-lactate assay after ethanol extraction; Figure 1D: means of at least three independent experiments, duplicate assays, ± SEM. — Figure 1D; Results: Sensitivity of SCLC cell lines to AZD3965

Cell number relative to untreated cells under the same condition: Direct cell counting (Figure 1C); at least three independent experiments, duplicate assays, ± SEM; caption specifies paired two-tailed t-test. — Figure 1C-D caption and accompanying Results

AZD-3965 In Vivo Studies

In an abortion-prone mouse pregnancy model, oral AZD3965 at 50 mg/kg twice daily from E5.5 to E10.5 reduced embryo resorption versus PBS-treated AP controls (p < 0.001). The tested 25 and 100 mg/kg groups did not establish a significant resorption benefit in the reported comparisons; a monotonic dose response was not demonstrated. [3]

In Long Evans rats, AZD3965 at 1,000 mg/kg by oral gavage once daily for four days decreased visual acuity. Acuity recovered to pre-dose levels seven days after dosing stopped. This adverse functional response limits general safety interpretations of preclinical efficacy findings. [4]

Embryo resorption in an abortion-prone mouse model

Animal study · Normal and abortion-prone mouse pregnancies; 6–8-week-old breeding mice [3]

The moderate AZD3965 dose reduced embryo resorption in AP mice. Low and high doses did not have a significant resorption benefit established by the reported comparisons.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Embryo resorption rate: resorptions / (formed fetuses + resorptions) × 100%Between-group comparison 50 mg/kg bid versus AP control: p < 0.001; n = 5–8; mean ± SEM[3]

Conditions shared by the study groups

Route
Oral administration (Figure 9A: i.g.)
Frequency
Twice daily (bid)
Treatment course
E5.5 to E10.5; euthanasia at E10.5
Vehicle
PBS used for controls; exact active-drug formulation not separately specified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Low dose
25 mg/kg
PBS-treated AP control; PBS-treated normal pregnancy BALB/c male × CBA/J female groupA significant resorption reduction is not established for this dose in the reported Results or Figure 9C annotations.[3]
Moderate dose
50 mg/kg
PBS-treated AP control; PBS-treated normal pregnancy BALB/c male × CBA/J female groupEmbryo resorption rate decreased versus AP control, p < 0.001.[3]
High dose
100 mg/kg
PBS-treated AP control; PBS-treated normal pregnancy BALB/c male × CBA/J female groupA significant resorption reduction is not established for this dose in the reported Results or Figure 9C annotations.[3]
Low dose
Model: Abortion-prone DBA/2 male × CBA/J female pregnancy model
Reported limits: Per-group n is not individually stated; caption gives n = 5–8 for resorption.
Moderate dose
Model: Abortion-prone DBA/2 male × CBA/J female pregnancy model
Reported limits: Per-group n is not individually stated; caption gives n = 5–8 for resorption.
High dose
Model: Abortion-prone DBA/2 male × CBA/J female pregnancy model
Reported limits: Per-group n is not individually stated; caption gives n = 5–8 for resorption.
Methods and source locations

Compound reported in the paper: AZD3965; Compound label in the paper: A14186 (reported catalog number)

Results apply to the paper-reported material and model; no analytical equivalence or current Adooq lot validation is established.

Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E

Embryo resorption rate: resorptions / (formed fetuses + resorptions) × 100%: Macroscopic classification by smaller size/darker appearance. Multigroup comparisons: one-way ANOVA; no exact percentages inferred from plot. — Figure 9B-C and caption; Animals; Statistical analyses; final Results paragraph

Low dose · Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E

Moderate dose · Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E

High dose · Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E

Repeat-dose visual acuity and recovery

Animal study · Long Evans hooded rats, 7–9 weeks old; five males and five females per group [4]

High-dose AZD3965 caused a reversible decrease in visual acuity under the tested four-day regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Visual acuity by optomotor reflexQualitative time course with reported significance Decreased during dosing; recovered to pre-dose levels 7 days after cessation; Figure 3 marks p < 0.05 versus vehicle[4]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
4 days; recovery observations through day 11
Vehicle
Water with 0.5% w/v hydroxypropyl methylcellulose and 0.1% w/v Tween 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AZD3965 repeat dosing
1,000 mg/kg
Vehicle-treated groupVisual acuity decreased during dosing and recovered to pre-dose levels 7 days after cessation.[4]
AZD3965 repeat dosing
Model: Long Evans hooded rats; five males and five females per group
Reported limits: Day 5 used five treated males only and compared with vehicle data from the preceding day.
Methods and source locations

Compound reported in the paper: AZD3965

Results apply to the paper-reported material and model; no analytical equivalence or current Adooq lot validation is established.

Figure 3 and caption; Results 3.2; Methods 2.2-2.4, 2.7, 2.9-2.10

Visual acuity by optomotor reflex: OptoMotry maximum resolvable grating frequency; measurements 1 h post-dose on days 1 and 4, followed by recovery measurements. Standard error bars; repeated-measures random-effects model with animal random effect; one-sided treatment comparisons without multiple-testing adjustment. — Figure 3 caption; Results 3.2; Methods 2.4 and 2.10

AZD3965 repeat dosing · Figure 3 and caption; Results 3.2; Methods 2.2-2.4, 2.7, 2.9-2.10

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1448671-31-5
Applications MCT1 inhibitor
Formula C21H24F3N5O5S
Molecular Weight 515.5
SMILES
O=C1N(C(C)C)C2=C(C(C(N3OC[C@@](C)(O)C3)=O)=C(CC4=C(C(F)(F)F)NN=C4C)S2)C(N1C)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (186.22 mM)
Water Insoluble
Ethanol 96 mg/mL (186.22 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AZD-3965 Research References

  1. [1] Nicola J Curtis, Lorraine Mooney, Lorna Hopcroft, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity Oncotarget (2017). PMID: 29050199 DOI: 10.18632/oncotarget.18215 Source material
  2. [2] Radosław Polański, Cassandra L Hodgkinson, Alberto Fusi, et al. Activity of the Monocarboxylate Transporter 1 inhibitor AZD3965 in Small Cell Lung Cancer Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24277449 DOI: 10.1158/1078-0432.CCR-13-2270 Source material
  3. [3] Gao, Lu, Xu, Qian-Han, Ma, Li-Na, et al. Trophoblast-derived Lactic Acid Orchestrates Decidual Macrophage Differentiation via SRC/LDHA Signaling in Early Pregnancy International Journal of Biological Sciences (2022). PMID: 35002512 DOI: 10.7150/ijbs.67816 Source material
  4. [4] Annette E Allen, Elizabeth A Martin, Katherine Greenwood, et al. Effects of a monocarboxylate transport 1 inhibitor, AZD3965, on retinal and visual function in the rat British Journal of Pharmacology (2020). PMID: 32833237 DOI: 10.1111/bph.15239 Source material

Publications

1 publication citing this product

  1. Lu Gao, .et al. , Int J Biol Sci, 2022, Jan 1;18(2):599-616 PMID: 35002512

Added to your cart

View Cart Checkout
Loading...